The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2022 | Addressing the major challenges to CAR-T therapy in AML
In this fascinating discussion, John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and Rizwan Romee, MD, Dana-Farber Cancer Institute, Boston, MA, discuss the major challenges to CAR-T therapy in acute myeloid leukemia (AML), highlighting recent work on strategies aiming to overcome these hurdles. Prof. DiPersio, Dr Romee, and Dr Gill start by outlining the benefits of CAR-natural killer (NK) therapy over CAR-T therapy, before exploring the best approaches to transduce NK cells. Moving forward, the experts discuss why some patients with AML may not respond to CAR-T therapy, highlighting the impact of T-cell fitness and cytokine release syndrome (CRS) on the success of immunotherapy. They also discuss novel treatment strategies including macrophage CARs for myelodysplastic syndromes (MDS) and targeting NPM1-mutated AML with anti-NPM1c CAR-NKs, and discuss the challenge of finding new target antigens in AML. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.
